Health Guide
Metabolic Health
Plain-English summaries: what it is, what it was studied for, safety and regulatory status, plus mixing and dosing charts.
An investigational once-weekly medicine from Eli Lilly that activates three hormone receptors: GIP, GLP-1 and glucagon.
A 16-amino-acid peptide encoded by mitochondrial DNA, studied for energy metabolism, insulin sensitivity and exercise.
Two compounds that act on growth-hormone signaling in different ways.
An FDA-approved prescription peptide that activates both GIP and GLP-1 receptors.
The active ingredient in several FDA-approved GLP-1 medicines.
An FDA-approved prescription peptide that reduces excess abdominal (visceral) fat in adults with HIV-associated lipodystrophy.
An investigational combination of an amylin analogue and a GLP-1 receptor agonist.
A 16-amino-acid fragment of human growth hormone studied for fat metabolism.
An investigational long-acting amylin analogue for weight management.
An experimental small molecule, not a peptide, that blocks the enzyme NNMT.
A compounded injectable blend of nutrients, usually methionine, choline and L-carnitine, often with inositol or B vitamins.
A compounded injectable blend of methionine, inositol and choline (MIC) with vitamin B12, often added to weight-loss programs.
A dual GLP-1/glucagon receptor agonist approved in China in 2025 for weight management and type 2 diabetes.
An investigational once-weekly peptide that activates both GLP-1 and glucagon receptors, studied for obesity and fatty liver disease (MASH).
An experimental small molecule, not a peptide, that activates estrogen-related receptors (ERRs) involved in energy use.
A three-ingredient combination often discussed for fat loss and body composition.
An experimental compound designed to destroy the blood supply of white fat tissue.
An investigational once-weekly amylin receptor agonist being developed by Lilly for obesity.
A four-amino-acid bioregulator peptide studied for pancreatic function and age-related changes in blood-sugar control.